21:19 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Tremfya superior to Cosentyx in head-to-head Phase III trial

Janssen Biotech Inc. said Tremfya guselkumab met the primary endpoint of improving PASI 90 response rate vs. Cosentyx secukinumab from Novartis AG (NYSE:NVS; SIX:NOVN) in the Phase III ECLIPSE trial to treat moderate to severe...
20:58 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Imfinzi-tremelimumab combo fails Phase III for head and neck cancer

In yet another setback for tremelimumab, AstraZeneca plc (LSE:AZN; NYSE:AZN) said the anti-CTLA-4 mAb in combination with PD-L1 inhibitor Imfinzi durvalumab missed the primary endpoint of improving overall survival (OS) compared with standard of care...
18:39 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Netris' NTN1 inhibitor safe in Phase I for solid tumors

Netris Pharma S.A.S. (Lyon, France) said escalating doses of up to 20 mg/kg IV NP137 every two weeks were well tolerated with no dose-limiting toxicities (DLTs) reported in a Phase I trial in 19 patients...
23:31 , Dec 12, 2018 |  BC Extra  |  Clinical News

Tremfya superior to Cosentyx in head-to-head Phase III trial

Janssen Biotech Inc. said Tremfya guselkumab met the primary endpoint of improving PASI 90 response rate vs. Cosentyx secukinumab from Novartis AG (NYSE:NVS; SIX:NOVN) in the Phase III ECLIPSE trial to treat moderate to severe...
23:59 , Dec 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies suggest combinations of bispecific small molecules targeting fluorescein and CAIX, PSMA or FOLR1 plus anti-fluorescein CAR T cells could help treat triple-negative breast cancer (TNBC). The bispecific adapter molecules consist...
23:59 , Dec 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies suggest a vaccine based on a tetanus toxoid-MUC1 conjugate could help treat MUC1-expressing breast cancer. The conjugate consists of a 22-mer human MUC1 peptide conjugated to tetanus toxoid carrier protein,...
17:46 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

ASH presentations hint at future of BCMA CARs

Enhanced persistence and redirection of universal cells are among approaches companies are using to create the next generation of BCMA (tumor necrosis factor receptor superfamily member 17; TNFRSF17; CD269)-targeted CAR T cell therapies for multiple...
13:28 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Clostridium Patient sample, cell culture and mouse studies suggest inhibiting VEGF-A, VEGFR-2 or HIF1 could help treat Clostridium difficile infection (CDI). In serum samples from patients, levels of VEGF-A were higher than in samples...
00:51 , Dec 4, 2018 |  BC Extra  |  Clinical News

Weekend ASH presentations hint at future of BCMA CARs

Enhanced persistence and redirection of universal cells are among approaches companies are using to create the next generation of BCMA (tumor necrosis factor receptor superfamily member 17; TNFRSF17; CD269)-targeted CAR T cell therapies for multiple...
19:04 , Nov 30, 2018 |  BC Week In Review  |  Financial News

Adrenomed raises €24M series D

Adrenomed AG (Hennigsdorf, Germany) raised €24 million ($27.3 million) in a series D round led by new investors Wellington Partners and HBM Healthcare Investments, with participation from existing investors ILB, ExpoCapital GmbH and company founders....